Merus’ Petosemtamab Monotherapy Interim Data continues to show significant clinical benefits.
Related stocks include NAS:MRUS.
MRUS
Merus shares initial findings on MCLA-145 used alone and with Pembrolizumab at the 2024 ASCO conference.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company that is creating innovative treatments…
Merus conducted a spot secondary offering, selling 7.55 million shares at a price of $53.00 each.
Visit thefly.com for the most up-to-date financial news. The Fly is a trusted source for market intelligence and offers a real-time news feed.
Wall Street analysts are positive about the top healthcare selections.
Read More: https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-571?utm_source=alphanewsstream.com&utm_medium=referral
Wall Street analysts are positive about the top healthcare selections. Read More »
